RFG Advisory LLC Reduces Stock Position in Axon Enterprise, Inc. (NASDAQ:AXON)

RFG Advisory LLC lessened its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 56.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,188 shares of the biotechnology company's stock after selling 1,511 shares during the quarter. RFG Advisory LLC's holdings in Axon Enterprise were worth $625,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in AXON. Fourth Dimension Wealth LLC purchased a new position in shares of Axon Enterprise in the fourth quarter worth approximately $30,000. Elequin Capital LP purchased a new position in shares of Axon Enterprise in the fourth quarter worth approximately $46,000. Stonebridge Financial Group LLC purchased a new position in shares of Axon Enterprise in the fourth quarter worth approximately $53,000. CoreFirst Bank & Trust purchased a new position in shares of Axon Enterprise in the fourth quarter worth approximately $59,000. Finally, Global Financial Private Client LLC lifted its holdings in Axon Enterprise by 11,100.0% during the first quarter. Global Financial Private Client LLC now owns 112 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 111 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company's stock.

Insiders Place Their Bets

In other news, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $540.99, for a total value of $5,409,900.00. Following the sale, the chief executive officer now directly owns 3,063,982 shares in the company, valued at approximately $1,657,583,622.18. This trade represents a 0.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeri Williams sold 307 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $552.72, for a total transaction of $169,685.04. Following the completion of the transaction, the director now directly owns 1,627 shares of the company's stock, valued at $899,275.44. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 43,969 shares of company stock worth $29,909,594 in the last three months. Corporate insiders own 4.40% of the company's stock.

Axon Enterprise Trading Up 0.4%

AXON stock opened at $791.85 on Friday. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. Axon Enterprise, Inc. has a twelve month low of $278.24 and a twelve month high of $798.16. The stock has a market capitalization of $61.65 billion, a price-to-earnings ratio of 204.61, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24. The firm's fifty day simple moving average is $643.89 and its two-hundred day simple moving average is $616.45.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The firm had revenue of $603.63 million for the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The business's revenue for the quarter was up 31.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.15 earnings per share. As a group, analysts anticipate that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on AXON. The Goldman Sachs Group lifted their price target on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a report on Wednesday, May 14th. Northcoast Research downgraded shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a report on Wednesday, February 19th. Craig Hallum downgraded shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a report on Monday, March 10th. Barclays lifted their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Finally, Bank of America lifted their price target on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Axon Enterprise currently has an average rating of "Moderate Buy" and an average price target of $699.55.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.